Abstract:Abstract Background COVID-19 is an infectious disease characterized by multiple respiratory and extrapulmonary manifestations, including gastrointestinal symptoms. Although recent studies have linked gut microbiota to infectious diseases such as influenza, little is known about the role of the gut microbiota in COVID-19 pathophysiology. Methods To better understand the host-gut microbiota interactions in COVID-19, we characterized the gut microbial community and gut barrier function using metagenomic and metaproteomic approaches in 63 COVID-19 patients and 8 non-infected controls. Both immunohematological parameters and transcriptional profiles were measured to reflect the immune response in COVID-19 patients. Results Altered gut microbial composition was observed in COVID-19 patients, which was characterized by decreased commensal species and increased opportunistic pathogenic species. Severe illness was associated with higher abundance of four microbial species (i.e., Burkholderia contaminans , Bacteroides nordii , Bifidobacterium longum , and Blautia sp. CAG 257), six microbial pathways (e.g., glycolysis and fermentation), and 10 virulence genes. These severity-related microbial features were further associated with host immune response. For example, the abundance of Bu. contaminans was associated with higher levels of inflammation biomarkers and lower levels of immune cells. Furthermore, human-origin proteins identified from both blood and fecal samples suggested gut barrier dysfunction in COVID-19 patients. The circulating levels of lipopolysaccharide-binding protein increased in patients with severe illness and were associated with circulating inflammation biomarkers and immune cells. Besides, proteins of disease-related bacteria (e.g., B. longum ) were detectable in blood samples from patients. Conclusions Our results suggest that the dysbiosis of the gut microbiome and the dysfunction of the gut barrier might play a role in the pathophysiology of COVID-19 by affecting host immune homeostasis.

Gut microbiota in COVID-19: new insights from inside

Gut Microbiota Improves Prognostic Prediction in Critically Ill COVID-19 Patients Alongside Immunological and Hematological Indicators

The relationship between gut microbiota and COVID-19 progression: new insights into immunopathogenesis and treatment

Gut microbiota in COVID-19: key microbial changes, potential mechanisms and clinical applications

Alterations of the gut microbiota in coronavirus disease 2019 and its therapeutic potential

Alterations in microbiota of patients with COVID-19: potential mechanisms and therapeutic interventions

Gut Microbiome Alterations in COVID-19

Potential Associations Between Microbiome and COVID-19

Alterations of the Gut Microbiota in Patients with Coronavirus Disease 2019 or H1N1 Influenza.

The Faecal Metabolome in COVID-19 Patients is Altered and Associated with Clinical Features and Gut Microbes

Traditional Chinese medicine against COVID-19: Role of the gut microbiota

Modulated Gut Microbiota for Potential COVID-19 Prevention and Treatment

Gut mycobiota alterations in patients with COVID-19 and H1N1 and associations with immune and gastrointestinal symptoms

Gut Microbiota and COVID-19: Potential Implications for Disease Severity

Fecal multi-omics analysis reveals diverse molecular alterations of gut ecosystem in COVID-19 patients

Gut Microbiota Imbalance in Colorectal Cancer Patients, the Risk Factor of COVID-19 Mortality

Integrated gut virome and bacteriome dynamics in COVID-19 patients

Gut microbiome alterations and gut barrier dysfunction are associated with host immune homeostasis in COVID-19 patients

FMT: A Potential Therapeutic and Rehabilitative Intervention for COVID-19

COVID-19 and the Human Gut Microbiome: An Under-Recognized Association

Gut Mycobiota Alterations in Patients with COVID-19 and H1N1 Infections and Their Associations with Clinical Features